Wedbush Weighs in on Chimerix’s Q2 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Equities research analysts at Wedbush reduced their Q2 2025 earnings per share estimates for shares of Chimerix in a report issued on Monday, December 9th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter, down from their previous estimate of ($0.26). Wedbush currently has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at ($0.04) EPS.

A number of other brokerages have also commented on CMRX. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a report on Wednesday. StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Stock Performance

Shares of CMRX opened at $2.95 on Thursday. The firm has a market cap of $265.32 million, a P/E ratio of -3.14 and a beta of 1.02. Chimerix has a twelve month low of $0.75 and a twelve month high of $3.39. The firm’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $0.96.

Institutional Trading of Chimerix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Valeo Financial Advisors LLC grew its stake in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 69,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Chimerix in the 2nd quarter valued at about $137,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.